Table 1.
Baseline study population demographics.
| Monotherapy Group (n = 411) | Integrative Therapy Group (n = 1405) | p-Value | |
|---|---|---|---|
| Sex | < 0.001 | ||
| Male | 242 (58.9%) | 526 (37.4%) | |
| Female | 169 (41.1%) | 879 (62.6%) | |
| Age | 0.061 | ||
| 60–64 | 167 (40.6%) | 578 (41.1%) | |
| 65–69 | 120 (29.2%) | 419 (29.8%) | |
| 70–74 | 63 (15.3%) | 254 (18.1%) | |
| 75–79 | 41 (36.7%) | 121 (8.6%) | |
| ≥80 | 20 (4.9%) | 33 (2.4%) | |
| Comorbidity | |||
| Alcohol-related diseases | 20 (4.9%) | 75 (5.3%) | 0.706 |
| Cardiovascular diseases | 137 (33.3%) | 580 (41.3%) | 0.004 |
| Chronic kidney diseases | 44 (10.7%) | 163 (11.6%) | 0.615 |
| Chronic obstructive pulmonary diseases | 219 (53.3%) | 881 (62.7%) | <0.001 |
| Dementia | 19 (4.6%) | 74 (5.3%) | 0.602 |
| Depression | 44 (10.7%) | 230 (16.4%) | 0.005 |
| Diabetes mellitus | 125 (30.4%) | 467 (33.2%) | 0.283 |
| Hyperlipidemial | 90 (21.9%) | 364 (25.9%) | 0.099 |
| Hypertension | 242 (58.9%) | 853 (60.7%) | 0.505 |
| Charlson Comorbidity Index | <0.001 | ||
| 0 | 118 (28.7%) | 246 (17.5%) | |
| 1 | 128 (31.1%) | 440 (31.3%) | |
| 2 | 83 (20.2%) | 378 (26.9%) | |
| ≥3 | 82 (20.0%) | 341 (24.3%) | |
| Biomedicine Drug | <0.001 | ||
| Yes | 299 (72.8%) | 1132 (80.6%) | |
| No | 112 (27.3%) | 273 (19.4%) | |
| Treatment period in biomedicine (days) | 0.207 | ||
| 1 | 204 (49.6%) | 747 (53.2%) | |
| ≥2 | 207 (50.4%) | 658 (46.8%) | |
| Hospitalization period in biomedicine (days) | |||
| 0 | 360 (87.6%) | 1281 (91.2%) | 0.03 |
| ≥1 | 51 (12.4%) | 124 (8.8%) | |
| # of visiting biomedicine hospital | 0.158 | ||
| 1 | 362 (88.1%) | 1271 (90.5%) | |
| ≥2 | 49 (11.9%) | 134 (9.5%) |